Molecular Cancer Therapeutics Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Molecular Cancer Therapeutics 7, 1365-1375, June 1, 2008. Published Online First June 4, 2008;
doi: 10.1158/1535-7163.MCT-08-0091
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow All Versions of this Article:
1535-7163.MCT-08-0091v1
7/6/1365    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Wu, C.-C.
Right arrow Articles by Yang, P.-C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, C.-C.
Right arrow Articles by Yang, P.-C.

Research Articles: Therapeutics, Targets, and Development

Modulation of the expression of the invasion-suppressor CRMP-1 by cyclooxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBP{alpha}

Cheng-Chung Wu1, Jau-Chen Lin1,4, Shuenn-Chen Yang1, Chiu-Wen Lin1, Jeremy J.W. Chen2,5, Jin-Yuan Shih3, Tse-Ming Hong2 and Pan-Chyr Yang1,2,3

1 Institute of Biomedical Sciences, Academia Sinica; 2 NTU Center of Genomic Medicine, National Taiwan University; 3 Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; 4 School of Cosmeceutics, China Medical University; 5 Institutes of Biomedical Sciences and Molecular Biology, National Chung-Hsing University, Taichung, Taiwan

Requests for reprints: Pan-Chyr Yang, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung Shan South Road, Taipei, Taiwan. Phone: 886-2-2356-2185; Fax: 886-2-2358-2867. E-mail: pcyang{at}ntu.edu.tw

Abstract

Collapsin response mediator protein-1 (CRMP-1) controls neural development and axonal growth but also acts as a cancer invasion suppressor. In this study, we investigated the transcriptional regulation of CRMP-1 expression. Using a serial deletion strategy, we identified a basal promoter region between nucleotides -100 and -180 in the 5' flanking region of CRMP-1 (nucleotides -1,920 to +50) that contains multiple putative Sp1 and C/EBP{alpha} sites. Site-directed mutagenesis and deletion analysis revealed that the two C/EBP{alpha} sites, from nucleotides -122 to -133 and from nucleotides -101 to -113, are the most important regulatory elements. Gel-shift and antibody supershift assays showed that Sp1 protein was also present at this C/EBP{alpha} site, which overlaps with a Sp1 site. Overexpression of Sp1 decreased CRMP-1 promoter activity and protein expression, whereas overexpression of C/EBP{alpha} produced the opposite effect. Chromatin immunoprecipitation assays confirmed that Sp1 and C/EBP{alpha} compete for binding at the overlapping C/EBP{alpha} and Sp1 sites and reciprocally regulate CRMP-1 expression. Overexpression of cyclooxygenase-2 (COX-2) decreased CRMP-1 mRNA and protein expression. Conversely, the COX-2 inhibitor, celecoxib, induced a dose-dependent increase in CRMP-1 expression. COX-2 inhibition also decreased Sp1-DNA complex formation and inhibited cell invasion. We conclude that transcription of the invasion suppressor, CRMP-1, is reciprocally regulated at the promoter region by C/EBP{alpha} and Sp1. COX-2 inhibitors increase CRMP-1 expression by inhibiting Sp1-DNA complex formation and enhancing DNA binding of C/EBP{alpha} at the promoter. [Mol Cancer Ther 2008;7(6):1365–75]


Footnotes

Grant support: National Research Program for Genomic Medicine grants DOH95-TD-G-111-010, DOH95-TG-G-111-012, DOH96-TD-G-111-09, and DOH96-TD-G-111-011.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: C-C. Wu and J-C. Lin contributed equally to this work. T-M. Hong and P-C. Yang codirected the project and contributed equally.

6 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

7 http://www.ifti.org/cgi-bin/ifti/Tfsitescan.pl

Received 1/24/08; revised 3/28/08; accepted 3/31/08.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.